Antibiotic Research UK participates in BIA Webinar on ‘Antimicrobial Resistance: Overcoming the risk to global health’

Professor Colin Garner, Chief Executive, was asked by the UK Bioindustry Association to present about Antibiotic Research UK at a Webinar held on Thursday 23 July 2015. Antibiotic Research UK is proud to be BIA’s charity of 2015. The Webinar showcased the activities of a number of UK antibiotic drug development companies including Discuva, RedX Pharma and Novabiotics. The Webinar was the first that the BIA had run in this format and was very successful. Perhaps in future, Antibiotic Research UK could run its own webinar’s to publicise the activities of the charity! To see Antibiotic Research UK’s slides which were presented at the webinar click ANTRUK_BIA Webinar slides. To see the entire webinar click on BIA’s Youtube feed https://www.youtube.com/watch?v=eb2i1ZQkVYc

Antibiotic Research UK Our Mission To protect and promote the health of the public in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic resistant bacterial infectious diseases

Antibiotic Research UK Our Mission To protect and promote the health of the public in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic resistant bacterial infectious diseases AMR Mortality – 2050 O’Neill commission estimates 10 million deaths worldwide pa in 2050 at a cost of $60-100 trillion between now and then Antibiotic Research UK

• Formed by a network of internationally recognised scientists and clinicians from 14 of Britain’s top universities and 14 specialty pharma companies
• Registered with Charity Commission in July 2014
• Constitution adopted at first AGM held in York in August 2014 Charity Organisation Our People 2015/7/24 Antibiotic Research UK –
• 2015 ARBs MUST fill the gap before invention of new antibiotics ANTRUK’s Research Programmes
• Early projects will focus on Antibiotic Resistance Breakers • Aim is to study Gram-ve bacteria initially (approx 50% of hospital infections)
• Species selected – Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumanni and Pseudomonas aeruginosa
• Only antibiotic resistant strains will be screened
• Antibiotic resistance to be broken against carbapenems, fluoroquinolones, aminoglycosides and polymyxinsa